IL231907B - Compounds and compositions for treatment of transthyretin-associated amyloidosis - Google Patents

Compounds and compositions for treatment of transthyretin-associated amyloidosis

Info

Publication number
IL231907B
IL231907B IL231907A IL23190714A IL231907B IL 231907 B IL231907 B IL 231907B IL 231907 A IL231907 A IL 231907A IL 23190714 A IL23190714 A IL 23190714A IL 231907 B IL231907 B IL 231907B
Authority
IL
Israel
Prior art keywords
transthyretin
compositions
compounds
treatment
related amyloidosis
Prior art date
Application number
IL231907A
Other languages
English (en)
Hebrew (he)
Other versions
IL231907A0 (en
Original Assignee
Som Innovation Biotech S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47076222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL231907(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Som Innovation Biotech S L filed Critical Som Innovation Biotech S L
Publication of IL231907A0 publication Critical patent/IL231907A0/en
Publication of IL231907B publication Critical patent/IL231907B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/603Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL231907A 2011-10-24 2014-04-03 Compounds and compositions for treatment of transthyretin-associated amyloidosis IL231907B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11382326 2011-10-24
PCT/EP2012/070945 WO2013060668A1 (en) 2011-10-24 2012-10-23 New therapy for transthyretin-associated amyloidosis

Publications (2)

Publication Number Publication Date
IL231907A0 IL231907A0 (en) 2014-05-28
IL231907B true IL231907B (en) 2018-05-31

Family

ID=47076222

Family Applications (1)

Application Number Title Priority Date Filing Date
IL231907A IL231907B (en) 2011-10-24 2014-04-03 Compounds and compositions for treatment of transthyretin-associated amyloidosis

Country Status (19)

Country Link
US (5) US9610270B2 (https=)
EP (1) EP2770988B1 (https=)
JP (1) JP6068484B2 (https=)
KR (1) KR102017354B1 (https=)
CN (1) CN103889407B (https=)
AU (2) AU2012327275B2 (https=)
BR (1) BR112014009322B1 (https=)
CA (1) CA2852808C (https=)
CL (1) CL2014000893A1 (https=)
CY (1) CY1118151T1 (https=)
ES (1) ES2593038T3 (https=)
IL (1) IL231907B (https=)
MX (2) MX385516B (https=)
PL (1) PL2770988T3 (https=)
PT (1) PT2770988T (https=)
RU (2) RU2747536C2 (https=)
SG (2) SG11201401215VA (https=)
WO (1) WO2013060668A1 (https=)
ZA (1) ZA201402546B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2747536C2 (ru) * 2011-10-24 2021-05-06 Сом Инновэйшн Биотек, С.Л. Новая терапия транстиретин-ассоциированного амилоидоза
DK3185957T3 (da) * 2014-08-29 2022-08-29 Alnylam Pharmaceuticals Inc Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
EP3275433A1 (en) 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
US20210008209A1 (en) * 2018-03-12 2021-01-14 Corino Therapeutics, Inc. Combination therapy for ttr amyloidosis
EP3976017A4 (en) * 2019-05-31 2023-06-14 Plex Pharmaceuticals, Inc. PHARMACOLOGICAL SUBSTANCES FOR THE TREATMENT OF PROTEIN AGGREGATION DISEASES OF THE EYE
JP2023549533A (ja) * 2020-11-13 2023-11-27 プレックス ファーマスーティカルズ,インク 眼の状態を処置するための薬理剤
CN114324693B (zh) * 2022-01-14 2023-01-13 大连博源医学科技有限公司 一种血液中转甲状腺素蛋白(ttr)四聚体浓度测定的预处理方法和检测方法
WO2024081554A2 (en) * 2022-10-10 2024-04-18 Corino Therapeutics, Inc. Modified release tolcapone formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
WO1998027972A2 (en) 1996-12-23 1998-07-02 Texas A & M University Anti-amyloidogenic agents
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
PT1372682E (pt) 2001-03-15 2012-08-03 Proteotech Inc Catequinas para o tratamento de fibrilogénese em doença de alzheimer, doença de parkinson, amiloidose αa sistémica e outras perturbações amiloides
WO2004065614A2 (en) 2002-01-29 2004-08-05 Protemix Corporation Limited Suppression of cytotoxic protein conformers
US20040175382A1 (en) 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
AU2005215136A1 (en) 2004-02-20 2005-09-01 Novartis Ag DPP-IV inhibitors for treating neurodegeneration and cognitive disorders
CN1921856A (zh) * 2004-02-20 2007-02-28 诺瓦提斯公司 用于治疗神经变性疾病和认知障碍的dpp-iv抑制剂
KR20070032700A (ko) * 2004-05-20 2007-03-22 폴드알엑스 파마슈티칼스, 인크. 트랜스티레틴을 안정화하고 트랜스티레틴 미스폴딩을억제하기 위한, 2-((헤테로)아릴)-벤즈옥사졸 화합물 및유도체, 그리고 조성물 및 방법
WO2006026555A2 (en) 2004-08-30 2006-03-09 Seo Hong Yoo Neuroprotective effect of solubilized udca in focal ischemic model
GB2429645A (en) 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
US20120016037A1 (en) 2006-07-24 2012-01-19 Frank Toppo Method for prevention and treatment of Alzheimers
GB0718718D0 (en) 2007-09-25 2007-11-07 Pentraxin Therapeutics Ltd Compound and use thereof
DE102010010572A1 (de) 2010-03-08 2011-09-08 Mahle International Gmbh Trockenseparator
RU2747536C2 (ru) * 2011-10-24 2021-05-06 Сом Инновэйшн Биотек, С.Л. Новая терапия транстиретин-ассоциированного амилоидоза

Also Published As

Publication number Publication date
US9610270B2 (en) 2017-04-04
HK1198432A1 (en) 2015-04-24
US20170304243A1 (en) 2017-10-26
US11564899B2 (en) 2023-01-31
MX347784B (es) 2017-05-12
AU2017202670B2 (en) 2019-06-06
AU2012327275A2 (en) 2014-04-17
JP2014530842A (ja) 2014-11-20
US20200390733A1 (en) 2020-12-17
EP2770988B1 (en) 2016-07-20
RU2623062C2 (ru) 2017-06-21
RU2017119539A (ru) 2018-11-09
BR112014009322A2 (pt) 2017-04-18
AU2012327275B2 (en) 2017-03-02
MX385516B (es) 2025-03-18
RU2017119539A3 (https=) 2020-06-29
PL2770988T3 (pl) 2017-01-31
KR20140090161A (ko) 2014-07-16
MX2014004863A (es) 2014-05-27
ES2593038T3 (es) 2016-12-05
NZ623267A (en) 2015-11-27
BR112014009322B1 (pt) 2022-05-10
AU2012327275A1 (en) 2014-04-17
US10786473B2 (en) 2020-09-29
US10449169B2 (en) 2019-10-22
US20140296188A1 (en) 2014-10-02
IL231907A0 (en) 2014-05-28
RU2747536C2 (ru) 2021-05-06
CL2014000893A1 (es) 2014-09-05
BR112014009322A8 (pt) 2018-01-16
CN103889407A (zh) 2014-06-25
US20190091188A1 (en) 2019-03-28
PT2770988T (pt) 2016-09-05
US10045956B2 (en) 2018-08-14
CA2852808A1 (en) 2013-05-02
SG10201609933WA (en) 2017-02-27
JP6068484B2 (ja) 2017-01-25
RU2014114930A (ru) 2015-12-10
KR102017354B1 (ko) 2019-09-02
AU2017202670A1 (en) 2017-05-11
SG11201401215VA (en) 2014-08-28
ZA201402546B (en) 2015-07-29
CA2852808C (en) 2021-07-06
CN103889407B (zh) 2017-03-15
US20200138760A1 (en) 2020-05-07
WO2013060668A1 (en) 2013-05-02
CY1118151T1 (el) 2017-06-28
EP2770988A1 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
EP2675909A4 (en) GLUCOSYLSTEVIA COMPOSITION
EP2720561A4 (en) Stevia-COMPOSITION
EP2713762A4 (en) Stevia-COMPOSITION
EP2736491A4 (en) BEPOTASTIN COMPOSITION
EP2706981A4 (en) COSMETIC COMPOSITIONS
HUE041891T2 (hu) Berendezés ipari célokra használt víz kezelésére
HUE043171T2 (hu) Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
LT2791160T (lt) Modifikuotos mrnr sudėtys
PL3443957T3 (pl) Związki i kompozycje stosowane w leczeniu nowotworów
HRP20180809T1 (hr) Inhibicijski spojevi metaloenzima
DK2635282T3 (da) Sammensætninger til behandling af myelofibrose
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
BR112014000033A2 (pt) compostos para o tratamento de dependência química
IL231061A0 (en) Antibacterial compounds and methods for use
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
IL228030A0 (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
IL231907B (en) Compounds and compositions for treatment of transthyretin-associated amyloidosis
DK2734212T3 (da) Sammensætninger omfattende diclofenac til behandling af postoperativ smerte
BR112014004416A2 (pt) composições e métodos para o tratamento de doenças neurodegenerativas
PL2672957T3 (pl) Nowe kompozycje do leczenia mukowiscydozy
IL231092A0 (en) Treatment of rhinitis
EP2732807A4 (en) COSMETIC COMPOSITION
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
EP2785176A4 (en) ANTIMICROBIAL COMPOSITIONS AND CORRESPONDING METHODS

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed